BDX

Business Context and Reporting Period

Company: Becton, Dickinson and Company (BD)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended December 31, 2025 (First Quarter of Fiscal Year 2026)
Key Corporate Event: On February 9, 2026, BD completed the spin-off of its Biosciences and Diagnostic Solutions business and its combination with Waters Corporation. This transaction resulted in a $4 billion cash distribution to BD and will result in the Life Sciences segment being reported as discontinued operations in future filings.

Key Financial Metrics

Margins: Gross profit margin was 45.9% for Q1 2026 compared to 43.3% in Q1 2025. Operating margin was 10.5% compared to 8.8% in the prior year.

Material Changes vs. Prior Period

• Revenue Growth: Revenues increased 1.6% year-over-year, driven primarily by a 1.2% favorable foreign currency impact. Organic growth (volume/other) was 0.3% and pricing contributed 0.1%.
• Profitability: Net income increased 26% to $382 million. This was driven by higher operating income ($552M vs $453M) and a lower effective tax rate impact from discrete items compared to the prior year.
• Segment Performance:
  • Connected Care: Revenue grew 5.5% (4.7% FX-neutral) driven by Medication Management Solutions and Advanced Patient Monitoring.
  • Interventional: Revenue grew 5.8% (5.1% FX-neutral) with double-digit growth in Urology and Critical Care.
  • Life Sciences: Revenue declined 8.3% (10.5% FX-neutral) due to lower sales in Diagnostic Solutions and Biosciences, impacted by research funding dynamics and vaccine demand.
• Costs: Integration, restructuring, and transaction expenses increased to $111 million from $92 million, largely due to separation-related costs for the Waters transaction.

Guidance, Outlook, and Risks

Management Commentary & Outlook:

• Shareholder Returns: BD repurchased $250 million of common stock in Q1 2026. Management expects to use approximately $2 billion of the $4 billion cash distribution from the Waters transaction for an accelerated share repurchase program in Q2 2026. The remainder is expected for debt repayment.
• Tariffs: Tariffs adversely impacted Q1 2026 operating expenses. Management expects a continued adverse impact on operating expenses for fiscal year 2026 and potentially beyond, depending on trade policy developments.
• Strategic Priorities: The "Excellence Unleashed" strategy focuses on competing, innovating, and delivering operational excellence.

Risks and Contingencies:

• Regulatory Matters: BD is subject to an FDA Consent Decree regarding Alaris infusion pumps. A Warning Letter was received in November 2024 regarding the Dispensing quality management system, with an accrued liability of $83 million for remediation costs. An El Paso facility inspection resulted in an "Official Action Indicated" classification in January 2026.
• Litigation: Significant product liability claims remain, including approximately 6,905 hernia repair device claims and 2,765 implantable port claims. Total accruals for product liability and legal matters were $1.7 billion as of December 31, 2025.
• Environmental: Ongoing litigation regarding ethylene oxide (EtO) emissions in Georgia, with a recent jury award of $20 million in compensatory damages (punitive phase mistrial).

Investor Verification Checklist

• Waters Transaction Impact: Verify the timing and accounting treatment of the $4 billion cash distribution and the classification of the Life Sciences segment as discontinued operations in future reports.
• Tariff Exposure: Assess the specific magnitude of tariff impacts on operating margins for the remainder of fiscal 2026 and the effectiveness of mitigation strategies.
• Regulatory Remediation Costs: Monitor the $83 million accrued liability for the FDA Warning Letter and potential additional costs related to the Consent Decree and El Paso facility inspection.
• Share Repurchase Execution: Confirm the execution of the planned $2 billion accelerated share repurchase in Q2 2026.
• Life Sciences Decline: Evaluate the sustainability of the revenue decline in the Life Sciences segment prior to its spin-off and the impact on overall portfolio mix.